NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Red Right Hand, thanks for pointing out that the Poly-ICLC trial is a Ph II that completes in 2025. Yes, I think they're going for the long tail, but I also believe the trial is far enough along that MHRA could determine that they've seen enough! We've seen the FDA approve Ph II drugs in the US because they've seen enough evidence, particularly with an orphan drug, as we are denoted. Why wouldn't MHRA do it?